Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77580.780.2432%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

Pyxis Oncology Inc

PYXSNASDAQ
Trade with Public
Trade with Public
$3.44
0.206.17%
At close: Sep 1, 5:00 PM EST
$3.41
-0.0295-0.86%
After Hours: 6:53 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Pyxis Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pyxis Oncology (PYXS).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

10Buy
1Hold
Consensus RatingBuy# Analysts11Avg. Consensus PT$8Upside to Avg. PT+128.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026HC Wainwright & Co.Swayampakula RamakanthMaintainedBuy$7
Aug 3, 2026Wells FargoDerek ArchilaInitiateOverweight$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
Benzinga Newsdesk

This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. Analysts have mixed opinions on SCHW stock.
Avi Kapoor

PRO
Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $12

Wells Fargo analyst Derek Archila initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Overweight rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $9 to $7.
Benzinga Newsdesk

PRO
Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved